Low Levels of Serum Apolipoprotein AI and AII in Senile Dementia

No abstract is available for this paper.

• Publication year

  1994

• Venue

  The Japanese journal of psychiatry and neurology

• Publication date

  1994-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1440-1819.1994.tb03019.xPMID 7891423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease

  2006cited by this paper
• Apolipoprotein E ∈4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases

  1993cited by this paper
• Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

  1993cited by this paper
• Apolipoprotein E : binding to soluble Alzheimer's β-amyloid

  1993cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

  1993cited by this paper
• Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

  1993cited by this paper
• Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

  1993cited by this paper
• Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

  1991cited by this paper
• Serum lipoprotein pattern variations in dementia and ischemic stroke

  1990cited by this paper
• Variant apolipoprotein AI as a major constituent of a human hereditary amyloid.

  1988cited by this paper
• Purification and characterization of a senile amyloid-related antigenic substance (apoSASSAM) from mouse serum. apoSASSAM is an apoA-II apolipoprotein of mouse high density lipoproteins.

  1986cited by this paper
• High homology is present in the primary structures between murine senile amyloid protein (ASSAM) and human apolipoprotein A‐II

  1986cited by this paper
• HDL-cholesterol in dementia.

  1985cited by this paper
• High-density lipoprotein cholesterol in differential diagnosis of senile dementia.

  1985cited by this paper
• HDL-CHOLESTEROL IN DEMENTIA

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Improved method for simultaneous determination of cholesterol in high- and low-density lipoproteins.

  1979cited by this paper
• Cerebral blood flow in dementia.

  1975cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Associations of 35 Serum and Urine Biomarkers With Vascular Dementia—A Mendelian Randomization Study

  2025cites this paper
• Serum Biomarkers of Vascular Dysfunction, Neuropsychiatric Symptoms, and Clinical Severity of Alzheimer's Disease: A Cross-sectional Study.

  2025cites this paper
• The Role of APOA-I in Alzheimer’s Disease: Bridging Peripheral Tissues and the Central Nervous System

  2025cites this paper
• Role of Apolipoproteins in Neurodegenerative Diseases

  2023cites this paper
• Association of Circulating Apolipoprotein AI Levels in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• The Role of High-Density Lipoprotein in Lowering Risk of Dementia in the Elderly: A Review

  2022cites this paper
• Exosomal Aβ-Binding Proteins Identified by “In Silico” Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease

  2021cites this paper
• Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer’s Disease: Systematic Review and Meta-Analysis

  2021cites this paper
• Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer’s disease

  2021cites this paper
• Alternatives to amyloid for Alzheimer's disease therapies—a symposium report

  2020cites this paper
• Blood lipid markers are associated with hippocampal viscoelastic properties and memory in humans

  2020cites this paper
• Paraoxonase Role in Human Neurodegenerative Diseases

  2020cites this paper
• Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease

  2019cites this paper
• BOLOGICAL MARKERS FOR LONGEVITY AND DISEASES AND USES THEREOF

  2017cites this paper
• Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.

  2016cites this paper
• Association of Hyperlipidaemia with Vascular Dementia among Stroke Patients Attending a Tertiary Level Hospital in Bangladesh

  2016cites this paper
• Syphilitic dementia and lipid metabolism

  2016cites this paper
• Statins for the prevention of dementia.

  2016cites this paper
• Genetic and environmental factors in vascular dementia: an update of blood brain barrier dysfunction

  2016cites this paper
• Lipids and Lipoproteins in Alzheimer’s Disease

  2015cites this paper
• HDL and glucose metabolism: current evidence and therapeutic potential

  2015cites this paper
• High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism

  2015cites this paper
• Identification of potential serum and urine biomarkers for patients with prostate cancer using lectin-based proteomic analyses / Jaime Jacqueline Jayapalan

  2015cites this paper
• Atherosclerosis, biomarkers of atherosclerosis and Alzheimer's disease

  2014cites this paper
• Statins for the treatment of dementia.

  2014cites this paper
• Intravenously Injected Human Apolipoprotein A‐I Rapidly Enters the Central Nervous System via the Choroid Plexus

  2014cites this paper
• High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease.

  2014cites this paper
• Cochrane review on ‘Statins for the treatment of dementia’

  2013cites this paper
• Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases

  2012cites this paper
• Apolipoproteins and amyloid fibril formation in atherosclerosis

  2011cites this paper
• The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer

  2010cites this paper
• Apolipoprotein A-I Deficiency Increases Cerebral Amyloid Angiopathy and Cognitive Deficits in APP/PS1ΔE9 Mice*

  2010cites this paper
• Intersection between metabolic dysfunction, high fat diet consumption, and brain aging

  2010cites this paper
• P3‐391: Statins for the treatment of dementia

  2010cites this paper
• Effect of overexpressing apolipoprotein A-I in an animal model of Alzheimer's disease

  2010cites this paper
• Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease.

  2010cites this paper
• An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis

  2009influential citation
• Statins for the prevention of dementia (Review)

  2009cites this paper
• Statins for the prevention of dementia.

  2009cites this paper
• Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta‐analysis

  2008cites this paper
• No association of CETP genotype with cognitive function or age-related cognitive change.

  2007cites this paper
• The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study.

  2007cites this paper
• The Honolulu-Asia Aging Study

  2007cites this paper
• A genotype of exceptional longevity is associated with preservation of cognitive function

  2006cites this paper
• Genetic and Vascular Risk Factors for Cognitive Decline and Cerebral Small-Vessel Disease

  2006cites this paper
• Invited Commentary Invited Commentary: Lipoproteins and Dementia—Is It the Apolipoprotein A-I?

  2006cites this paper
• Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease.

  2006cites this paper
• Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

  2006cites this paper
• Impact of plasma lipids and time on memory performance in healthy elderly without dementia

  2005cites this paper
• Relation of plasma lipids to Alzheimer disease and vascular dementia.

  2004cites this paper
• Apolipoproteins and β Amyloid Transport Pathway

  2002cites this paper
• Plasma HDL levels highly correlate with cognitive function in exceptional longevity.

  2002cites this paper
• Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease

  2001cites this paper
• Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease.

  2000cites this paper
• Early Diagnosis of Alzheimer’s Disease

  2000cites this paper
• Peripheral Markers of Alzheimer’s

  2000cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Status of Risk Factors for Vascular Dementia

  1998cites this paper